Emerging drugs for the treatment of tobacco dependence: 2014 update (Q28236453)

Expert Opinion on Emerging Drugs

Europe PubMed Central

title

Emerging drugs for the treatment of tobacco dependence: 2014 update (English)

0 references

author name string

Muhamad Y Elrashidi

series ordinal

1

0 references

Jon O Ebbert

series ordinal

2

0 references

language of work or name

English

0 references

publication date

June 2014

0 references

published in

0 references

volume

19

0 references

issue

2

0 references

page(s)

243-60

0 references

1 reference

https://api.crossref.org/works/10.1517/14728214.2014.899580

Motivating and helping smokers to stop smoking

20 April 2017

1 reference

https://api.crossref.org/works/10.1517/14728214.2014.899580

A systematic review of the relationships between craving and smoking cessation

20 April 2017

1 reference

https://api.crossref.org/works/10.1517/14728214.2014.899580

Cardiovascular events associated with smoking cessation pharmacotherapies: a network meta-analysis

20 April 2017

1 reference

https://api.crossref.org/works/10.1517/14728214.2014.899580

Varenicline: an alpha4beta2 nicotinic receptor partial agonist for smoking cessation

20 April 2017

1 reference

https://api.crossref.org/works/10.1517/14728214.2014.899580

Two decades of smoking cessation treatment research on smokers with depression: 1990-2010

20 April 2017

1 reference

https://api.crossref.org/works/10.1517/14728214.2014.899580

Nicotine and endogenous opioids: Neurochemical and pharmacological evidence

20 April 2017

1 reference

https://api.crossref.org/works/10.1517/14728214.2014.899580

Reboxetine for acute treatment of major depression: systematic review and meta-analysis of published and unpublished placebo and selective serotonin reuptake inhibitor controlled trials

20 April 2017

1 reference

https://api.crossref.org/works/10.1517/14728214.2014.899580

Topiramate in the treatment of substance-related disorders: a critical review of the literature

20 April 2017

1 reference

https://api.crossref.org/works/10.1517/14728214.2014.899580

Cytisine for smoking cessation: a literature review and a meta-analysis

20 April 2017

1 reference

https://api.crossref.org/works/10.1517/14728214.2014.899580

Efficacy of cytisine in helping smokers quit: systematic review and meta-analysis

20 April 2017

1 reference

https://api.crossref.org/works/10.1517/14728214.2014.899580

Placebo-controlled trial of cytisine for smoking cessation

20 April 2017

1 reference

https://api.crossref.org/works/10.1517/14728214.2014.899580

The role of cystine-glutamate exchange in nicotine dependence in rats and humans

20 April 2017

1 reference

https://api.crossref.org/works/10.1517/14728214.2014.899580

Bupropion and the risk of sudden death: a self-controlled case-series analysis using The Health Improvement Network

20 April 2017

1 reference

https://api.crossref.org/works/10.1517/14728214.2014.899580

Translational research in nicotine dependence

20 April 2017

1 reference

https://api.crossref.org/works/10.1517/14728214.2014.899580

Tobacco use in 3 billion individuals from 16 countries: an analysis of nationally representative cross-sectional household surveys

20 April 2017

1 reference

https://api.crossref.org/works/10.1517/14728214.2014.899580

21st-century hazards of smoking and benefits of cessation in the United States

21 January 2018

1 reference

https://api.crossref.org/works/10.1517/14728214.2014.899580

The return on investment of a Medicaid tobacco cessation program in Massachusetts

21 January 2018

1 reference

https://api.crossref.org/works/10.1517/14728214.2014.899580

The scientific case that nicotine is addictive.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517/14728214.2014.899580

Pharmacology of nicotine: addiction, smoking-induced disease, and therapeutics

21 January 2018

1 reference

https://api.crossref.org/works/10.1517/14728214.2014.899580

Nicotine-, tobacco particulate matter- and methamphetamine-produced locomotor sensitisation in rats

21 January 2018

1 reference

https://api.crossref.org/works/10.1517/14728214.2014.899580

The neurobiology of nicotine addiction: bridging the gap from molecules to behaviour

21 January 2018

1 reference

https://api.crossref.org/works/10.1517/14728214.2014.899580

Nicotinic receptors in addiction pathways

21 January 2018

1 reference

https://api.crossref.org/works/10.1517/14728214.2014.899580

Early smoking onset and risk for subsequent nicotine dependence: a monozygotic co-twin control study

21 January 2018

1 reference

https://api.crossref.org/works/10.1517/14728214.2014.899580

Translational research in medication development for nicotine dependence

21 January 2018

1 reference

https://api.crossref.org/works/10.1517/14728214.2014.899580

The return to smoking: 1-year relapse trajectories among female smokers

21 January 2018

1 reference

https://api.crossref.org/works/10.1517/14728214.2014.899580

Pharmacotherapy for treating tobacco dependence: what is the ideal duration of therapy?

21 January 2018

1 reference

https://api.crossref.org/works/10.1517/14728214.2014.899580

Adverse effects and tolerability of medications for the treatment of tobacco use and dependence

21 January 2018

1 reference

https://api.crossref.org/works/10.1517/14728214.2014.899580

Adherence to treatment for tobacco dependence: association with smoking abstinence and predictors of adherence

21 January 2018

1 reference

https://api.crossref.org/works/10.1517/14728214.2014.899580

Effects of copayment on initiation of smoking cessation pharmacotherapy: an analysis of varenicline reversed claims

21 January 2018

1 reference

https://api.crossref.org/works/10.1517/14728214.2014.899580

Clinical practice. Treatment of tobacco use and dependence

21 January 2018

1 reference

https://api.crossref.org/works/10.1517/14728214.2014.899580

Boosting population quits through evidence-based cessation treatment and policy

21 January 2018

1 reference

https://api.crossref.org/works/10.1517/14728214.2014.899580

Helping smokers quit: understanding the barriers to utilization of smoking cessation services

21 January 2018

1 reference

https://api.crossref.org/works/10.1517/14728214.2014.899580

Individual differences in preferences for and responses to four nicotine replacement products

21 January 2018

1 reference

https://api.crossref.org/works/10.1517/14728214.2014.899580

The nicotine inhaler: clinical pharmacokinetics and comparison with other nicotine treatments

21 January 2018

1 reference

https://api.crossref.org/works/10.1517/14728214.2014.899580

Efficacy of a nicotine mouth spray in smoking cessation: a randomised, double-blind trial.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517/14728214.2014.899580

Successful treatment with a nicotine lozenge of smokers with prior failure in pharmacological therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1517/14728214.2014.899580

Pharmacokinetics of a nicotine polacrilex lozenge

21 January 2018

1 reference

https://api.crossref.org/works/10.1517/14728214.2014.899580

Varenicline and combination nicotine replacement therapy are the most effective pharmacotherapies for treating tobacco use.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517/14728214.2014.899580

Clinical strategies to enhance the efficacy of nicotine replacement therapy for smoking cessation: a review of the literature.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517/14728214.2014.899580

Varenicline and bupropion sustained-release combination therapy for smoking cessation

21 January 2018

1 reference

https://api.crossref.org/works/10.1517/14728214.2014.899580

Psychological mediators of bupropion sustained-release treatment for smoking cessation

21 January 2018

1 reference

https://api.crossref.org/works/10.1517/14728214.2014.899580

Effect of Stress and Bupropion on Craving, Withdrawal Symptoms, and Mood in Smokers

21 January 2018

1 reference

https://api.crossref.org/works/10.1517/14728214.2014.899580

Varenicline for tobacco dependence

21 January 2018

1 reference

https://api.crossref.org/works/10.1517/14728214.2014.899580

Combination treatment with varenicline and nicotine replacement therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1517/14728214.2014.899580

Is a combination of varenicline and nicotine patch more effective in helping smokers quit than varenicline alone? A randomised controlled trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1517/14728214.2014.899580

Combination varenicline and bupropion SR for tobacco-dependence treatment in cigarette smokers: a randomized trial.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517/14728214.2014.899580

Effect of maintenance therapy with varenicline on smoking cessation: a randomized controlled trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1517/14728214.2014.899580

Increasing the dose of varenicline in patients who do not respond to the standard dose

21 January 2018

1 reference

https://api.crossref.org/works/10.1517/14728214.2014.899580

Efficacy of varenicline, an alpha4beta2 nicotinic acetylcholine receptor partial agonist, vs placebo or sustained-release bupropion for smoking cessation: a randomized controlled trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1517/14728214.2014.899580

Varenicline, an alpha4beta2 nicotinic acetylcholine receptor partial agonist, vs sustained-release bupropion and placebo for smoking cessation: a randomized controlled trial.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517/14728214.2014.899580

FDA warns of adverse events linked to smoking cessation drug and antiepileptics

21 January 2018

1 reference

https://api.crossref.org/works/10.1517/14728214.2014.899580

The Promises and Pitfalls of Reboxetine

21 January 2018

1 reference

https://api.crossref.org/works/10.1517/14728214.2014.899580

Smoking, smoking cessation, and major depression

21 January 2018

1 reference

https://api.crossref.org/works/10.1517/14728214.2014.899580

Major depression and stages of smoking. A longitudinal investigation

21 January 2018

1 reference

https://api.crossref.org/works/10.1517/14728214.2014.899580

Nortriptyline for smoking cessation: a review

21 January 2018

1 reference

https://api.crossref.org/works/10.1517/14728214.2014.899580

Genetic variants in the serotonin transporter influence the efficacy of bupropion and nortriptyline in smoking cessation

21 January 2018

1 reference

https://api.crossref.org/works/10.1517/14728214.2014.899580

ADHD medication reduces cotinine levels and withdrawal in smokers with ADHD

21 January 2018

1 reference

https://api.crossref.org/works/10.1517/14728214.2014.899580

Atomoxetine treatment for nicotine withdrawal: a pilot double-blind, placebo-controlled, fixed-dose study in adult smokers

21 January 2018

1 reference

https://api.crossref.org/works/10.1517/14728214.2014.899580

Effects of atomoxetine on cognitive function and cigarette smoking in schizophrenia

21 January 2018

1 reference

https://api.crossref.org/works/10.1517/14728214.2014.899580

Off-label use of atomoxetine in adults: is it safe?

21 January 2018

1 reference

https://api.crossref.org/works/10.1517/14728214.2014.899580

Effects of a single dose of baclofen on self-reported subjective effects and tobacco smoking

21 January 2018

1 reference

https://api.crossref.org/works/10.1517/14728214.2014.899580

The GABA B agonist baclofen reduces cigarette consumption in a preliminary double-blind placebo-controlled smoking reduction study.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517/14728214.2014.899580

Labetalol treatment enhances the attenuation of tobacco withdrawal symptoms by nicotine in abstinent smokers

21 January 2018

1 reference

https://api.crossref.org/works/10.1517/14728214.2014.899580

Effects of the nicotinic receptor antagonist mecamylamine on ad-lib smoking behavior, topography, and nicotine levels in smokers with and without schizophrenia: a preliminary study

21 January 2018

1 reference

https://api.crossref.org/works/10.1517/14728214.2014.899580

A randomized, controlled trial to assess the efficacy and safety of a transdermal delivery system of nicotine/mecamylamine in cigarette smokers.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517/14728214.2014.899580

A randomized trial of naltrexone for smoking cessation.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517/14728214.2014.899580

Neurobiological mechanisms involved in nicotine dependence and reward: participation of the endogenous opioid system

21 January 2018

1 reference

https://api.crossref.org/works/10.1517/14728214.2014.899580

Efficacy of naltrexone in smoking cessation: a preliminary study and an examination of sex differences

21 January 2018

1 reference

https://api.crossref.org/works/10.1517/14728214.2014.899580

The impact of depressive symptoms on the efficacy of naltrexone in smoking cessation

21 January 2018

1 reference

https://api.crossref.org/works/10.1517/14728214.2014.899580

Developments in pharmacotherapy for tobacco dependence: past, present and future

21 January 2018

1 reference

https://api.crossref.org/works/10.1517/14728214.2014.899580

The endogenous cannabinoid system modulates nicotine reward and dependence

21 January 2018

1 reference

https://api.crossref.org/works/10.1517/14728214.2014.899580

ANKK1/DRD2 locus variants are associated with rimonabant efficacy in aiding smoking cessation: pilot data

21 January 2018

1 reference

https://api.crossref.org/works/10.1517/14728214.2014.899580

Efficacy of a dose range of surinabant, a cannabinoid receptor blocker, for smoking cessation: a randomized controlled clinical trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1517/14728214.2014.899580

Failure to improve cigarette smoking abstinence with transdermal selegiline cognitive behavior therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1517/14728214.2014.899580

Effects of selegiline (L-deprenyl) during smoking and short-term abstinence

21 January 2018

1 reference

https://api.crossref.org/works/10.1517/14728214.2014.899580

A preliminary placebo-controlled trial of selegiline hydrochloride for smoking cessation

21 January 2018

1 reference

https://api.crossref.org/works/10.1517/14728214.2014.899580

A randomized controlled trial of oral selegiline plus nicotine skin patch compared with placebo plus nicotine skin patch for smoking cessation

21 January 2018

1 reference

https://api.crossref.org/works/10.1517/14728214.2014.899580

Selegiline transdermal system (STS) as an aid for smoking cessation

21 January 2018

1 reference

https://api.crossref.org/works/10.1517/14728214.2014.899580

A double-blind, placebo-controlled, randomized clinical trial of oral selegiline hydrochloride for smoking cessation in nicotine-dependent cigarette smokers

21 January 2018

1 reference

https://api.crossref.org/works/10.1517/14728214.2014.899580

Effects of tiagabine in combination with intravenous nicotine in overnight abstinent smokers

21 January 2018

1 reference

https://api.crossref.org/works/10.1517/14728214.2014.899580

Glutamatergic medications for the treatment of drug and behavioral addictions

21 January 2018

1 reference

https://api.crossref.org/works/10.1517/14728214.2014.899580

Topiramate for smoking cessation

21 January 2018

1 reference

https://api.crossref.org/works/10.1517/14728214.2014.899580

Use of oral topiramate to promote smoking abstinence among alcohol-dependent smokers: a randomized controlled trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1517/14728214.2014.899580

Effects of topiramate on cue-induced cigarette craving and the response to a smoked cigarette in briefly abstinent smokers

21 January 2018

1 reference

https://api.crossref.org/works/10.1517/14728214.2014.899580

Effects of topiramate in combination with intravenous nicotine in overnight abstinent smokers

21 January 2018

1 reference

https://api.crossref.org/works/10.1517/14728214.2014.899580

Preliminary evidence for gender-specific effects of topiramate as a potential aid to smoking cessation

21 January 2018

1 reference

https://api.crossref.org/works/10.1517/14728214.2014.899580

Effects of topiramate or naltrexone on tobacco use among male alcohol-dependent outpatients

21 January 2018

1 reference

https://api.crossref.org/works/10.1517/14728214.2014.899580

Effects of topiramate on smoking in patients with schizoaffective disorder, bipolar type

21 January 2018

1 reference

https://api.crossref.org/works/10.1517/14728214.2014.899580

Topiramate for smoking cessation and the importance to distinguish withdrawal-motivated consumption and cue-triggered automatisms.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517/14728214.2014.899580

Role of gamma-aminobutyric acid (GABA) and metabotropic glutamate receptors in nicotine reinforcement: potential pharmacotherapies for smoking cessation

21 January 2018

1 reference

https://api.crossref.org/works/10.1517/14728214.2014.899580

Drug may suppress the craving for nicotine

21 January 2018

1 reference

https://api.crossref.org/works/10.1517/14728214.2014.899580

Cytisine, the world's oldest smoking cessation aid.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517/14728214.2014.899580

Cytisine and the failure to market and regulate for human health

21 January 2018

1 reference

https://api.crossref.org/works/10.1517/14728214.2014.899580

The case for licensing cytosine now for smoking cessation is overwhelming

21 January 2018

1 reference

https://api.crossref.org/works/10.1517/14728214.2014.899580

Silver acetate interactions with nicotine and non-nicotine smoke components

21 January 2018

1 reference

https://api.crossref.org/works/10.1517/14728214.2014.899580

A placebo-controlled evaluation of the effects of buspirone on smoking cessation: differences between high- and low-anxiety smokers

21 January 2018

1 reference

https://api.crossref.org/works/10.1517/14728214.2014.899580

Efficacy of buspirone in smoking cessation: a placebo-controlled trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1517/14728214.2014.899580

D-Cycloserine attenuates reactivity to smoking cues in nicotine dependent smokers: a pilot investigation

21 January 2018

1 reference

https://api.crossref.org/works/10.1517/14728214.2014.899580

Effects of D-cycloserine on cue-induced craving and cigarette smoking among concurrent cocaine- and nicotine-dependent volunteers

21 January 2018

1 reference

https://api.crossref.org/works/10.1517/14728214.2014.899580

Occupancy of brain dopamine D3 receptors and drug craving: a translational approach.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517/14728214.2014.899580

Increasing the demand for and use of effective smoking-cessation treatments reaping the full health benefits of tobacco-control science and policy gains--in our lifetime

21 January 2018

1 reference

https://api.crossref.org/works/10.1517/14728214.2014.899580

The power of the press in smokers' attempts to quit

21 January 2018

1 reference

https://api.crossref.org/works/10.1517/14728214.2014.899580

The regulatory challenge of electronic cigarettes.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517/14728214.2014.899580

21 January 2018

1 reference

https://api.crossref.org/works/10.1517/14728214.2014.899580

Zebrafish for the Study of the Biological Effects of Nicotine

21 January 2018

1 reference

https://api.crossref.org/works/10.1517/14728214.2014.899580

Debunking myths about self-quitting. Evidence from 10 prospective studies of persons who attempt to quit smoking by themselves

21 January 2018

1 reference

https://api.crossref.org/works/10.1517/14728214.2014.899580